News

Results from a retrospective study favor younger matched unrelated donors for consideration in the donor selection for patients with myelodysplastic syndrome.

Srdan Verstovsek, MD, discussed maintaining hematocrit levels in patients with polycythemia vera as well as research on the use of rusfertide.

Bradley Monk, MD, FACCOG, FACS, discusses the creation and findings of the OUTBACK trial.

SWOG 1318 results are promising for extended blinatumomab use in patients with acute lymphoblastic leukemia.

A subgroup analysis of lenvatinib plus pembrolizumab showed similar results to the global population of patients with advanced renal cell carcinoma who participated in the phase 3 CLEAR trial.

Golidocitinib is showing promise for the treatment of relapsed or refractory peripheral T-cell lymphoma in an ongoing phase 1/2 clinical trial.

Rana R. McKay, MD, discusses KEYNOTE-564 and the future of adjuvant immunotherapy in renal cell carcinoma.

IO-202 for the treatment of patients with relapsed or refractory acute myeloid leukemia is a strategy under investigation in a phase 1, multicenter, open-label, dose-escalation and expansion study.

The FDA will conduct a speedy review of the supplemental biologics license application for lisocabtagene maraleucel as second-line treatment for adult patients with relapsed or refractory large B-cell lymphoma.

A phase 2 trial sought to evaluate the efficacy and safety of the combination of anlotinib and sintilimab in patients with recurrent advanced endometrial cancer.

Following a report of low CD4-positive T cell counts in a patient’s peripheral blood, the FDA placed a clinical hold on a phase 1 study of LB1901.

Treatment of indolent mantle cell lymphoma tumors may require an individualize approach, but frontline ibrutinib and rituximab is one possibility.

The FDA has accepted a new drug application for adagrasib for the treatment of patients with non-small cell lung cancer harboring KRAS G12C mutation.

Cancer Treatment Centers of America Phoenix, has achieved Magnet recognition by the American Nurses Credentialing Center.

In an interview with Targeted Oncology, Jorge Nieva, MD, provided a recap of the recent ODAC meeting and explained his stance against further research for frontline sintilimab plus chemotherapy for the treatment of patients with nonsquamous NSCLC.

Pancreatic tumor responses to sotorasib in CodeBreak 100 have significantly surpassed the 16% response rate achieved with FDA-approved therapies.

In the largest study of bone marrow-derived macrophages in post hematopoietic stem cell transplantation patients with a hematologic malignancy, results showed that donor derived cells from the myeloablative transplants accounted for 4.1-25% of microglial cells.

In an interview with Targeted Oncology, Lee Schwartzberg, MD, further discusses the findings of KEYNOTE-522 and pembrolizumab in patients with triple negative breast cancer.

Stephanie Lee, MD, MPH, discusses the effectiveness of ruxolitinib within various settings for patients with chronic graft-versus-host disease.

An application for FDA approval has been submitted for poziotinib as a potential treatment for patients with non–small cell lung cancer harboring HER2 exon 20 insertion mutations.

In an interview with Targeted Oncology™, Naomi B. Haas, MD, discussed how the research has pivoted toward exploring neoadjuvant treatment for patients with renal cell carcinoma.

Peter Martin, MD, discusses questions asked in regards to patient populations in a real-world study of treatment patterns and outcomes of mantle cell lymphoma.

The FDA’s Oncologic Drug Advisory Committee has voted against approval of the biologics license application for sintilimab plus pemetrexed and platinum-based chemotherapy for the treatment of nonsquamous non–small cell lung cancer without further clinical trial research.

In an interview with Targeted Oncology, Neal Shore discusses the findings of ARAMIS which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer, and its primary end point of metastasis-free survival.

In KEYNOTE-522, treatment with adjuvant pembrolizumab following neoadjuvant pembrolizumab with chemotherapy showed a statistically significant prolonged event-free survival in patients with high-risk early-stage triple-negative breast cancer.

In an interview with Targeted Oncology™, Ming Zhao, MD, discusses the results of the FOHAIC-1 clinical trial and how it compares to HAIC-FO for the treatment of HCC.

In an interview with Targeted Oncology, James Brugarolas, MD, PhD discussed promising updated survival data in metastatic renal cell carcinoma and investigational biomarkers to further advanced the field.

The novel oncolytic adenovirus, VCN-01 has been granted FDA orphan drug designation for retinoblastoma and will soon be investigated in a phase 2/3 clinical trial.

In an interview with Targeted Oncology, Toufic Kachaamy, MD, discussed in detail the role of the gastroenterology community in staging, diagnosing, and managing gastrointestinal malignancies.

Statistically significant improvement in progression-free survival has been shown with selinexor in patients with advanced or recurrent endometrial cancer, including those with wild-type p53.